Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MRT-2359 by Monte Rosa Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor...
MRT-6160 by Monte Rosa Therapeutics for Rheumatoid Arthritis: Likelihood of Approval
MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Rheumatoid Arthritis. According to GlobalData,...
MRT-6160 by Monte Rosa Therapeutics for Multiple Sclerosis: Likelihood of Approval
MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Multiple Sclerosis. According to GlobalData,...
MRT-6160 by Monte Rosa Therapeutics for Cutaneous Lupus Erythematosus: Likelihood of Approval
MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Cutaneous Lupus Erythematosus. According to...
MRT-6160 by Monte Rosa Therapeutics for Psoriasis: Likelihood of Approval
MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Psoriasis. According to GlobalData, Phase...
MRT-2359 by Monte Rosa Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Small-Cell Lung Cancer. According to...